Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease and end‑stage renal disease, and is characterized by persistent proteinuria and decreased glomerular filtration rate. Despite extensive efforts, the increasing incidence highlights the urgent need for more effective treatments. Histone methylation is a crucial epigenetic modification, and its alteration can destabilize chromatin structure, thereby regulating the transcriptional activity of specific genes. Histone methylation serves a substantial role in the onset and progression of various diseases. In patients with DKD, changes in histone methylation are pivotal in mediating the interactions between genetic and environmental factors. Targeting these modifications shows promise in ameliorating renal histological manifestations, tissue fibrosis and proteinuria, and represents a novel therapeutic frontier with the potential to halt DKD progression. The present review focuses on the alterations in histone methylation during the development of DKD, systematically summarizes its impact on various renal parenchymal cells and underscores the potential of targeted histone methylation modifications in improving DKD outcomes.
Keyphrases
- dna methylation
- genome wide
- chronic kidney disease
- end stage renal disease
- gene expression
- copy number
- peritoneal dialysis
- type diabetes
- transcription factor
- induced apoptosis
- cancer therapy
- risk factors
- dna damage
- oxidative stress
- metabolic syndrome
- machine learning
- adipose tissue
- climate change
- drug delivery
- risk assessment
- weight loss
- artificial intelligence
- glycemic control
- quality improvement
- genome wide identification